We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Topline results from a phase 2b/3 clinical trial of ...

Last July, the U.S. Food and Drug Administration (FDA) issued a notable approval for LEQEMBI® (lecanemab-irmb), the first medicine to slow the rate of cognitive decline in certain patients with early ...

Only a small fraction of older adults in the early stages of Alzheimer's disease (AD) meet eligibility criteria to receive treatment with newly approved anti-amyloid drugs, largely due to the presence ...

Phase 1 data shows sabirnetug (ACU193) is safe, reduces amyloid plaques, and supports ongoing Phase 2 trial for early Alzheimer’s disease. The press release implies that while there were positive ...

Please provide your email address to receive an email when new articles are posted on . Early Alzheimer’s care should include new FDA-approved therapies like lecanemab. The guidance suggests greater ...

The majority of patients with early-stage disease Alzheimer’s disease (AD) had stable or improved cognition over roughly 1 year of treatment with lecanemab (Leqembi), a real-world analysis showed. The ...

Anavex Life Sciences Corp. announced significant findings from the ATTENTION-AD trial, indicating that long-term treatment with the oral drug blarcamesine (ANAVEX®2-73) improved cognition and ...

LEADS aims to study 400 adults, ages 40 to 64, who have Alzheimer’s but no autosomal-dominant AD mutation. Some carry FTD or Parkinson's genes. Many likely became amyloid-positive in their 30s. The ...

NEW YORK — Budweiser is trotting out some familiar characters this year in its Super Bowl ad. The perennial NFL championship game marketer is bringing back fan-favorite team of Clydesdale horses and a ...

Tau PET has become a valuable research tool, but questions remain about how well tracer uptake reflects underlying tangles, how plaques influence this relationship, and how effectively the scans could ...